Lv1
100 积分 2023-05-04 加入
Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone
27天前
已完结
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
1个月前
已完结
Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma
1个月前
已完结
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies
2个月前
已完结
How I Treat Plasma Cell Leukemia
2个月前
已完结
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
2个月前
已完结
Osteoblasts inhibit NK cell killing function via RANK/RANKL in multiple myeloma
3个月前
已完结
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost
3个月前
已完结
Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma
3个月前
已完结
Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
3个月前
已完结
皖公网安备34019202002308
